RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).

Anica Högner,Kirstin Breithaupt,Alexander Stein,Axel Hinke,Mario Lorenz,Salah-Eddin Al-Batran,Peter C. Thuss-Patience

RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).

2019

Anica Högner
Kirstin Breithaupt
Alexander Stein
Axel Hinke
Mario Lorenz
Salah-Eddin Al-Batran
Peter C. Thuss-Patience

TPS4148Background: Combination of ramucirumab and paclitaxel resembles the standard treatment option in second line therapy with improvement of response rate and overall survival (REGARD, RAINBOW)....

Keywords:

Avelumab
Pathology
Paclitaxel
Gastro-
Oncology
Ramucirumab
Medicine
Adenocarcinoma
Internal medicine
esophageal adenocarcinoma
Standard treatment
Second-line therapy
second line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations